MAb52-4.2-ADC / MedAbome - LARVOL DELTA

Preclinical efficacy of a first-in-class anti-SLC3A2 ADC in hard-to-treat solid and hematologic malignancies (AACR 2026) - "These findings support MAb52-4.2-ADC as a promising therapeutic candidate for treating solid and hematologic malignancies, and potentially mitigating toxicity concerns. Ongoing studies aiming to support further clinical investigation include MAb52-4.2-ADC in patient-derived xenograft (PDX) gastrointestinal (GI) cancer models, along with retrospective analyses of its target expression in clinical tumor samples."

ADC • Preclinical • Breast Cancer • Colorectal Cancer • Gastric Cancer • Gastrointestinal Cancer • Hematological Malignancies • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor • Triple Negative Breast Cancer • SLC3A2 • SLC7A5